BiotechTube

Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dry Eye

Conditions

Dry Eye

Trial Timeline

Jun 17, 2024 → Oct 14, 2024

NCT ID
NCT06443775

About Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)

Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) is a pre-clinical stage product being developed by AbbVie for Dry Eye. The current trial status is completed. This product is registered under clinical trial identifier NCT06443775. Target conditions include Dry Eye.

What happened to similar drugs?

18 of 20 similar drugs in Dry Eye were approved

Approved (18) Terminated (4) Active (2)
✅CequaTM (Cyclosporine 0.09%) ophthalmic solutionSun PharmaceuticalApproved
✅Cyclosporine + Artificial tearSun PharmaceuticalApproved
✅nanomicellular cyclosporine 0.09% + LifitegrastSun PharmaceuticalApproved
✅Cyclosporine 0.09% Ophthalmic SolutionSun PharmaceuticalApproved
✅Hydroxypropylmethylcellulose + CarboxymethylcelluloseMerckApproved
✅azithromycin ophthalmic solution, 1% + Visine® for Contacts®MerckApproved
✅Azithromycin Ophthalmic Solution, 1% + PlaceboMerckApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06443775Pre-clinicalCompleted

Competing Products

20 competing products in Dry Eye

See all competitors
ProductCompanyStageHype Score
Cyclosporine Ophthalmic 0.05% Ophthalmic EmulsionSight SciencesPre-clinical
16
OK-101 + PlaceboOKYO PharmaPhase 2
25
ISV 101Sun PharmaceuticalPhase 2
27
CequaTM (Cyclosporine 0.09%) ophthalmic solutionSun PharmaceuticalApproved
43
0.09% cyclosporine A ophthalmic solutionSun PharmaceuticalPre-clinical
26
Cyclosporine + Artificial tearSun PharmaceuticalApproved
35
nanomicellular cyclosporine 0.09% + LifitegrastSun PharmaceuticalApproved
39
Cyclosporine 0.09% Ophthalmic SolutionSun PharmaceuticalApproved
43
Investigational Lubricating Eye Drop in a Novelia® bottle + Blink® Tears eye DropsJohnson & JohnsonPhase 2
35
diquafosol ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solution.Santen PharmaceuticalPre-clinical
26
Diquafosol sodium 3% + Sodium hyaluronate 0.1%Santen PharmaceuticalPhase 2
31
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionSanten PharmaceuticalPhase 3
40
Placebo ophthalmic solution and 3% DE-089 ophthalmic solutionSanten PharmaceuticalPhase 1
29
DE-089 ophthalmic solution + DE-089 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
35
SHR8028 eye drops + Vehicle eye drops.Jiangsu Hengrui MedicinePhase 3
40
SHR8058 eye drops + saline eye drops.Jiangsu Hengrui MedicinePhase 3
40
ABBV-444 + REFRESH OPTIVE UDAbbViePhase 3
47
AGN-242428 + AGN-231868 + Lifitegrast 5% Ophthalmic SolutionAbbViePhase 1/2
32
ABBV-444AbbViePhase 3
40
ABBV-319AbbViePhase 1
36